High Ki-67 and Vascular Endothelial Growth Factor (VEGF) Protein Expression as Negative Predictive Factor for Combined Neoadjuvant Chemotherapy in Young Age Stage III Breast Cancer

Sudarsa, I Wayan; Manuaba, Ida Bagus Tjakra Wibawa; Maliawan, Sri; Sutirtayasa, I Wayan Putu

doi:10.15562/bmj.v5i2.207

Cited by 4 publications

(7 citation statements)

References 5 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7, 8 Current studies showed no consistent results on the role of these factors in NAC response in young age breast cancer. 6 In this study, there was no significant association between confounding variables (age, tumor size, tumor type, tumor grade, and tumor subtype) with anthracycline-based neoadjuvant chemotherapy response in locally advanced young age breast cancer.…”

Section: Discussioncontrasting

confidence: 53%

“…However, the biggest problem was that the LABC in young patients was often detected in a later stage when the mass was considered a larger size and with aggressive characteristics. 6 Young age breast cancer patients are often diagnosed at an advanced stage, probably caused by ORIGINAL ARTICLE DFS (73.4% vs. 46.1%, P = 0.032), and OS (82.5% vs 56.4%, P = 0.022). 16 There are several predictive factors for NAC chemotherapy response, such as age, tumor size, histopathologic type, histologic grade, hormone receptor status (ER and PR), proliferative factor (HER2/neu and Ki-67), and inflammatory markers.…”

Section: Discussionmentioning

confidence: 99%

“…We found that 52.3% of patients had a negative neoadjuvant chemotherapy response (stable disease or progressive disease), and 48.7% of in NAC response in breast cancer at a young age. 6 The immune system has a pivotal role in breast cancer response to chemotherapy. 9 Neutrophils are generally considered a pro-tumor factor in several tumor types and are known to promote cancer cell proliferation, angiogenesis, and metastasis through multiple mechanisms, while lymphocytes play a role in anti-tumor immune reaction.…”

Section: Nlr and Clinical Response Towards Chemotherapymentioning

confidence: 99%

“…Anthracyclinebased chemotherapy is recommended for LABC. [4][5][6] Pathological complete response (pCR) after neoadjuvant chemotherapy is significantly related to prolonged diseasefree survival (DFS) and overall survival (OS) in LABC. 5 Breast cancer at a young age tended to have a worse prognosis partly due to more aggressive tumor characteristics, but their response to chemotherapy seems to be better.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Association of neutrophil-lymphocyte ratio (NLR) with the anthracycline-based neoadjuvant chemotherapy (NAC) clinical response in locally advanced breast cancer (LABC) in young women

2022

View full text Add to dashboard Cite

Background: Breast cancer in young women is one of the leading causes of cancer death in young women worldwide, including in Indonesia. Most patients come to the hospital at the advanced stage. Neoadjuvant chemotherapy (NAC) is the standard treatment for locally advanced breast cancer. However, half of breast cancer patients had a negative response to therapy. Methods: A retrospective cohort, analytic observational study to determine the association between NLR and anthracycline-based NAC clinical response in locally advanced young age breast cancer in Dr. Soetomo General Hospital, Surabaya. Results: We analyze a total of 44 patients. 81.8% had stage IIIB, 93.2% >50 mm tumor size. Most of the cases had invasive ductal carcinoma type (86.4%), grade 3 (52.3%), and Luminal B HER2-negative type (34.1%). 52.3% of patients had a negative clinical response. The mean NLR was 3.07 ± 1.69, with a cut-off value of 2.805. There was no significant association between age, tumor size, histopathological type, grade, and subtype with neoadjuvant chemotherapy clinical response. There was a significant relationship between NLR with anthracycline-based NAC clinical response in locally advanced young age breast cancer (p < 0.001). Conclusion: There was a significant relationship between NLR with the anthracycline-based neoadjuvant chemotherapy clinical response in young women with LABC.

show abstract

Section: Discussioncontrasting

confidence: 53%

Section: Discussionmentioning

confidence: 99%

Section: Nlr and Clinical Response Towards Chemotherapymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Association of neutrophil-lymphocyte ratio (NLR) with the anthracycline-based neoadjuvant chemotherapy (NAC) clinical response in locally advanced breast cancer (LABC) in young women

2022

View full text Add to dashboard Cite

show abstract

“…[28][29][30] In addition, an increase in vascular endothelial growth factor expression has been associated with impaired response to chemotherapy. [31,32] Taken together, the ability to image and analyze angiogenesis has the potential to detect changes in the breast cancer from disease progression or from response to treatment. In addition, since angiogenesis precedes transformation of mammary hyperplasia to malignancy, monitoring tumor-associated microvasculature change over time may assist in early detection and diagnosis of breast cancer in patients with abnormal mammograms.…”

Section: Introductionmentioning

confidence: 99%

Photoacoustic Computed Tomography of Breast Cancer in Response to Neoadjuvant Chemotherapy

Lin

Tong

et al. 2021

Advanced Science

View full text Add to dashboard Cite

Neoadjuvant chemotherapy (NAC) has contributed to improving breast cancer outcomes, and it would ideally reduce the need for definitive breast surgery in patients who have no residual cancer after NAC treatment. However, there is no reliable noninvasive imaging modality accepted as the routine method to assess response to NAC. Because of the inability to detect complete response, post‐NAC surgery remains the standard of care. To overcome this limitation, a single‐breath‐hold photoacoustic computed tomography (SBH‐PACT) system is developed to provide contrast similar to that of contrast‐enhanced magnetic resonance imaging, but with much higher spatial and temporal resolution and without injection of contrast chemicals. SBH‐PACT images breast cancer patients at three time points: before, during, and after NAC. The analysis of tumor size, blood vascular density, and irregularity in the distribution and morphology of the blood vessels on SBH‐PACT accurately identifies response to NAC as confirmed by the histopathological diagnosis. SBH‐PACT shows its near‐term potential as a diagnostic tool for assessing breast cancer response to systemic treatment by noninvasively measuring the changes in cancer‐associated angiogenesis. Further development of SBH‐PACT may also enable serial imaging, rather than the use of current invasive biopsies, to diagnose and follow indeterminate breast lesions.

show abstract

CD8+ Serum as a predictor of Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer

Qodir¹,

Umar²,

Darwin³

et al. 2019

J. Phys.: Conf. Ser.

View full text Add to dashboard Cite

CD8+ Cytotoxic T-cell Lymphocytes (CTLs) had a major role in tumour apoptosis. Meanwhile, chemotherapy could induce tumour cell apoptosis and enhance CTL response. Therefore, pre-treatment immune status might predict the ability of chemotherapy to eliminate cancer cells. The aim of this study was to evaluate the efficacy of neoadjuvant chemotherapy to CD8+ serum in locally advanced breast cancer patient. A randomized clinical trial has been conducted in Dr Mohammad Hoesin Palembang from October 2017 until January 2018. There were 30 samples who fulfil the inclusion criteria. All samples were taken neoadjuvant chemotherapy and analysis data was using SPSS ver.21. The range of age patient with locally advanced breast cancer in this study 30-66 y.o with mean 45±10.526 y.o. After neoadjuvant chemotherapy, the CD8+ serum was significantly decreased (p=0.000). CD8+ serum before chemotherapy has sensitivity 42.86% and specificity 43.48% to predict neoadjuvant chemotherapy response with cut off point 660.7 cell/mm3. Neoadjuvant chemotherapy decreases CD8+ significantly in locally advanced breast cancer patient.

show abstract

High Ki-67 and Vascular Endothelial Growth Factor (VEGF) Protein Expression as Negative Predictive Factor for Combined Neoadjuvant Chemotherapy in Young Age Stage III Breast Cancer

Cited by 4 publications

References 5 publications

Association of neutrophil-lymphocyte ratio (NLR) with the anthracycline-based neoadjuvant chemotherapy (NAC) clinical response in locally advanced breast cancer (LABC) in young women

Association of neutrophil-lymphocyte ratio (NLR) with the anthracycline-based neoadjuvant chemotherapy (NAC) clinical response in locally advanced breast cancer (LABC) in young women

Photoacoustic Computed Tomography of Breast Cancer in Response to Neoadjuvant Chemotherapy

CD8+ Serum as a predictor of Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer

Contact Info

Product

Resources

About